In March 2020, a phase 1/2a nonrandomized trial was launched by Nation Children’s Hospital, where 4 DMD patients received a single dose of SRP-9001(rAAVrh74.MHCK7.micro-dystrophin) delivered by limb IV therapy. This evidence concerns the gene DMD and Duchenne muscular dystrophy.